Provided by Tiger Trade Technology Pte. Ltd.

Senti Biosciences, Inc.

0.3886
-0.0474-10.87%
Post-market: 0.3836-0.0050-1.29%19:57 EDT
Volume:757.55K
Turnover:304.63K
Market Cap:12.10M
PE:-0.23
High:0.4400
Open:0.4360
Low:0.3600
Close:0.4360
52wk High:2.88
52wk Low:0.3331
Shares:31.14M
Float Shares:14.58M
Volume Ratio:2.71
T/O Rate:5.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7136
EPS(LYR):-2.7326
ROE:-466.46%
ROA:-65.57%
PB:-3.56
PE(LYR):-0.14

Loading ...

Senti Biosciences Unit Issues USD 4 Million Senior Secured Convertible Notes to Celadon Partners SPV 24

Reuters
·
Aug 21

Senti Biosciences Holdings Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 15

Senti Biosciences Q2 Net Loss Narrows to $12.75 Million; Revenue Turns to $17,000

Reuters
·
Aug 15

Senti Bio announces transaction to spin off Gene-Circuit-enabled pipeline

TIPRANKS
·
Jul 15

Senti Biosciences to Spin Off Senti-202 Assets to Celadon-backed Newco for CVR Worth up to $60 Million

Reuters
·
Jul 15

Senti Biosciences - CVR Milestones: $10 Mln for Bla Filing, $20 Mln for FDA Approval, $30 Mln for $200 Mln Sales

THOMSON REUTERS
·
Jul 15

Senti Biosciences - Newco to Buy Gene-circuit Pipeline Including Senti-202 for CVR up to $60 Mln

THOMSON REUTERS
·
Jul 15

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform

GlobeNewswire
·
Jul 15

NASDAQ Trade Halt Halt News Pending at 07:25 Am

Reuters
·
Jul 15

BRIEF-Senti Biosciences Says Offering 15.97 Million Shares Of Common Stock For Resale By Selling Securityholder

Reuters
·
Jun 19

Senti Biosciences - Offering 15.97 Mln Shares of Common Stock for Resale by Selling Securityholder - SEC Filing

THOMSON REUTERS
·
Jun 19

Senti Biosciences unit issues USD 10 million senior secured convertible notes to Celadon Partners SPV 24

Reuters
·
May 27

Analysts Conflicted on These Healthcare Names: Senti Biosciences (SNTI), ALX Oncology Holdings (ALXO) and Argenx Se (ARGX)

TIPRANKS
·
May 18

Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure

TIPRANKS
·
May 16

Senti Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
May 15

Chardan Raises Price Target on Senti Biosciences to $12 From $11, Keeps Buy Rating

MT Newswires Live
·
May 15

Senti Biosciences Q1 net loss narrows on cost reduction

Reuters
·
May 14

BRIEF-Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy

Reuters
·
May 14

Senti Biosciences Q1 EPS $(0.14) Beats $(0.36) Estimate, Sales $16.000K

Benzinga Earnings
·
May 14

Senti Biosciences Holdings Inc: Q1 Net Loss per Share $0.14

THOMSON REUTERS
·
May 14